Health, risks and disease in therapeutic functionalities of Glucagon-like peptide-1 receptoragonists (GLP-1RAs) concerning human susceptibility

作者
Chukwuma Sr Chrysanthus
标识
DOI:10.62046/gijams.2025.v03i05.002
摘要

This review expounds the unique sphere of medical care as it ardently advances the therapeutic concerns and essentials of GLP-1 drugs per the risk of inappropriate lean mass loss, possible resultant sarcopenia, with special reference in elderly or frail persons, irrespective of the beneficial outcomes of weight loss in chronic perturbations, such as type 2 diabetes, obesity, comorbidities, cardiovascular and neurodegenerative disorders. It is significant to have protective stances on muscle quality. The proportional augmentation of muscle lost with GLP-1 usage requires inter alia resistance training, high protein consumption, and potential medication research to ameliorate muscle wasting. These highlight the pertinence for an equilibrated modality to obesity, type 2 diabetes and cardiovascular disease management, incorporating lifestyle changes for the sustainability and preservation regarding the functional status and stance as well as the quality of life. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are comprehensively utilized for the improvement of glycemic regulation and inducement of weight loss in type 2 diabetes (T2D), however, therapeutic outcomes vary tremendously among patients. GLP-1 receptor agonists (GLP-1 RAs) are being advanced from diabetes and obesity therapeutic regimen to novel spheres for disparate emerging conditions, encompassing cardiovascular, hepatic, neurodegenerative, and autoimmune perturbations, and may provide benefits in attenuating muscle dissipation by lean muscle mass preservation, although human data are anecdotal necessitating ardent studies. GLP-1 drugs are not directly the causative agents in muscle shrinkage, however, the prominent weight loss these drugs potentiate may preponderate to the dissipation of lean body mass, including muscle. The muscle loss may exacerbate in persons with pre-existing sarcopenia or other untoward health states. Although, certain muscle loss is inherent to an extent of accelerated weight loss, it is conducive to realise that the access to resistance training and proper protein intake in patients, vulnerable or susceptible individuals may ameliorate this impact and cause weight loss to be safer and increasingly sustainable. Invariably, GLP-1 drugs are aetiologic agents in muscle shrinkage, concomitantly with accelerated weight dissipation as the body utilises both fat and muscle for energy, with certain research indicating lean body mass, in concert with muscle, responsible for appreciable amount of overall weight loss. In order for these to be averted, coupling of GLP-1 with a high-protein diet and resilient physical training or exercise for muscle mass preservation may be pertinent. The broad and progressive advantages of GLP-1 medicines, primordially emanated as therapeutic target developed for regulating blood glucose and weight which improved outcomes and good prognosis in persons presenting with heart, kidney, liver, arthritis, and sleep apnea dysfunctions. The actions mediated partly via anti-inflammatory and metabolic pathways, and certain benefits partly independent of the extent of weight loss. The role or function of GLP-1 receptor agonists encompass lowering of serum glucose concentration with concomitant management of metabolism in patients implicated.The emerging functionality of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) primordially developed for type 2 diabetes management, have evolved into prominence in obesity management, providing clinically purposeful and beneficial weight loss and numerous other clinical trials in health and disease for the future.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NexusExplorer的应助被Vincent采纳,获得10
2秒前
2秒前
yu完成签到 ,获得积分10
3秒前
9秒前
爆米花的应助被Vincent采纳,获得10
11秒前
15秒前
HAPPY完成签到,获得积分10
16秒前
桐桐的应助被Vincent采纳,获得10
17秒前
keleboys完成签到 ,获得积分10
19秒前
HMZ完成签到 ,获得积分10
21秒前
22秒前
HU完成签到 ,获得积分10
24秒前
25秒前
29秒前
小尾巴完成签到 ,获得积分10
32秒前
章鱼行者完成签到,获得积分10
32秒前
鲁文杰发布了新的文献求助10
33秒前
Maestro_S的应助被Vincent采纳,获得10
35秒前
36秒前
万能图书馆的应助被Vincent采纳,获得10
42秒前
42秒前
水静完成签到,获得积分10
43秒前
川川完成签到 ,获得积分10
47秒前
48秒前
科研通AI6.4的应助被Vincent采纳,获得10
48秒前
49秒前
标致访旋完成签到,获得积分10
50秒前
烂漫墨镜完成签到 ,获得积分10
53秒前
20230054发布了新的文献求助10
55秒前
55秒前
隐形曼青的应助被Vincent采纳,获得10
57秒前
鲁文杰完成签到,获得积分10
1分钟前
1分钟前
整齐百褶裙完成签到 ,获得积分10
1分钟前
Changhiwi完成签到 ,获得积分10
1分钟前
李健的小迷弟的应助被Vincent采纳,获得10
1分钟前
1分钟前
彳系禾完成签到 ,获得积分10
1分钟前
Jzhaoc580完成签到 ,获得积分10
1分钟前
冷艳凡灵完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577437
关于积分的说明 21852521
捐赠科研通 7788988
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482995